<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02439632</url>
  </required_header>
  <id_info>
    <org_study_id>Prulifloxacin aulut ZK-004</org_study_id>
    <nct_id>NCT02439632</nct_id>
  </id_info>
  <brief_title>A Multi-center, Randomized, Double-blind, Double-dummy Clinical Study to Evaluate the Safety and Efficacy of Prulifloxacin Film-coated Tablet for the Treatment of Acute Uncomplicated Lower Urinary Tract Infection With Levofloxacin Hydrochloride Tablet as Active Control</brief_title>
  <official_title>A Multi-center, Randomized, Double-blind, Double-dummy Clinical Study to Evaluate the Safety and Efficacy of Prulifloxacin Film-coated Tablet for the Treatment of Acute Uncomplicated Lower Urinary Tract Infection With Levofloxacin Hydrochloride Tablet as Active Control</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Lee's Pharmaceutical Limited</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Lee's Pharmaceutical Limited</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      prulifloxacin is not inferior to levofloxacin hydrochloride in treating acute uncomplicated
      lower urinary tract infection in chinese
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2014</start_date>
  <completion_date type="Actual">July 2015</completion_date>
  <primary_completion_date type="Actual">March 2015</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The efficacy of prulifloxacin film-coated tablet was meaured by the number of patient have been cured</measure>
    <time_frame>3 days</time_frame>
    <description>600mg single dose prolifloxacin is not inferior to Levoflxacin on low urine infection in Chinese</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The safety of prulifloxacin film-coated tablet was measured by the number fo AE and SAE</measure>
    <time_frame>3 days and 28 days</time_frame>
    <description>The susceptibility of infecting strains to prulifloxacin;
The rate of return to normal of WBC (white blood cell) in urine in treatment and control group
The safety and tolerability of prulifloxacin in adult patients with acute lower urinary tract infection</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">216</enrollment>
  <condition>Acute Lower Urinary Tract Infection</condition>
  <arm_group>
    <arm_group_label>prulifloxacin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Prulifloxacin film-coated tablet : 600 mg/tablet, oral administration of a single tablet.
Placebo of levofloxacin hydrochloride tablet without active components.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Levofloxacin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Levofloxacin hydrochloride tablet 250 mg/tablet, oral administration of a tablet daily for a total of 3 days.
Placebo of prulifloxacin film-coated tablet, without active components.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>prulifloxacin</intervention_name>
    <arm_group_label>prulifloxacin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Levofloxacin</intervention_name>
    <description>Levofloxacin hydrochloride tablet 250 mg/tablet, oral administration of a tablet daily for a total of 3 days.</description>
    <arm_group_label>Levofloxacin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Prulifloxacin Placebo</intervention_name>
    <description>Placebo of prulifloxacin film-coated tablet without active components.</description>
    <arm_group_label>Levofloxacin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Levofloxacin Placebo</intervention_name>
    <description>Placebo of levofloxacin hydrochloride tablet without active components.</description>
    <arm_group_label>prulifloxacin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patients aged 18 ~ 65 years old;

          2. Presence at least two of the following clinical signs and symptoms of acute
             uncomplicated lower urinary tract infection: dysuria, frequency, urgency and
             suprapubic pain) with onset of symptoms ≤ 72 hours prior to study entry;

          3. With pyuria: WBC &gt; 10/mm3 in unspun urine examined in a counting chamber or WBC &gt; 5/hp
             [or the Upper laboratory Norm (UNL)] in the resuspended sediment of a centrifuged
             aliquot of urine (or the UNL);

          4. Patient is willing to participate in the study and gives the signature of informed
             consent form;

        Exclusion Criteria:

          1. Presence of clinical signs and symptoms suggestive of pyelonephritis or complicated
             urinary tract infection (e.g., fever &gt; 37.5°C, chills, flank pain), or with factors
             associated with complicated urinary tract infections such as presence of an indwelling
             catheter or urologic abnormalities;

          2. Women who are pregnant, nursing or plan to become pregnant in the near future (i.e.,
             in three months). Women of childbearing potential (post-menopausal women must be
             amenorrheic for at least 12 months to be considered of non-childbearing potential)
             must have a negative serum pregnancy test at screening and must be willing to use an
             acceptable method of contraception to avoid pregnancy throughout the study. Acceptable
             methods of contraception include tubal ligation, oral contraceptive, barrier methods
             (intra-uterine device, diaphragm, female condom, male condom);

          3. Three or more episodes of acute uncomplicated UTI in the past 12 months;

          4. Patients with overactive bladder;

          5. Patients are hypersensitive to quinolones or with allergic constitution;

          6. Administration of xanthines, fenbufen, antibiotics or antibacterials within the two
             previous weeks;

          7. Patients with severe condition which need combination with other antibacterial agents
             or corticosteroids during the study;

          8. Impairment of gastrointestinal (GI) function or GI disease that may significantly
             alter the absorption of study drug (e.g., ulcerative disease, Inflammatory bowel
             disease, lactose intolerance, or malabsorption syndrome)

          9. Patients with severe liver or kidney disease, defined as serum ALT and AST ≥ 2.5 x ULN
             and creatinine ≥ 1.5 x ULN;

         10. Patients with severe heart disease or Q-T prolongation indicated by 12-lead ECG, or
             arrhythmia or acute myocardial ischemia;

         11. WBC &lt; 3.6 × 109/L or neutrophil &lt; 1.8 × 109/L, and/or platelets &lt; 90 × 109/L at
             screening;

         12. Patients with central nervous system disease or convulsion history, and/or with mental
             status unable to coordinate;

         13. Patients with malignant tumor or other severe background disease;

         14. Patients with severe immunodeficiency;

         15. Patients with a history of tendinopathy or who are currently having the disease,
             including tendinitis and tendon rupture;

         16. Patients treated with experimental drugs in the previous 4 weeks or currently;

         17. Considered inappropriate for the study by investigators, including patients who are
             unable or unwilling to show compliance with the protocol.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Peking Medical Union Hospital</name>
      <address>
        <city>Beijing</city>
        <zip>100000</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>May 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 4, 2014</study_first_submitted>
  <study_first_submitted_qc>May 6, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 12, 2015</study_first_posted>
  <last_update_submitted>July 15, 2015</last_update_submitted>
  <last_update_submitted_qc>July 15, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 16, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infection</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>Urinary Tract Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Levofloxacin</mesh_term>
    <mesh_term>Ofloxacin</mesh_term>
    <mesh_term>Prulifloxacin</mesh_term>
    <mesh_term>Fluoroquinolones</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

